KU004 induces G1 cell cycle arrest in human breast cancer SKBR-3 cells by modulating PI3K/Akt pathway

Biomedicine and Pharmacotherapy

Volumn 68, Issue 5, 2014, Pages 625-630

  Fu, Jing ^a   Tian, Chongchong ^a   Xing, Mengtao ^b   Wang, Xinzhi ^a   Guo, Hongli ^a   Sun, Lixin ^a   Sun, Lan ^c   Jiang, Zhenzhou ^a   Zhang, Luyong ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c JIANGSU KANION PHARMACEUTICAL CO   (China)

Author keywords

Cell cycle arrest; KU004; PI3K Akt

Indexed keywords

ANTIBODY; ANTINEOPLASTIC AGENT; CYCLIN D; CYCLIN DEPENDENT KINASE 4; EPIDERMAL GROWTH FACTOR RECEPTOR 2; KU 004; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P21; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL LINE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; WESTERN BLOTTING; BREAST TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECTS; ENZYMOLOGY; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; METABOLISM; PATHOLOGY; PHOSPHORYLATION; S PHASE CELL CYCLE CHECKPOINT; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; FEMALE; G1 PHASE CELL CYCLE CHECKPOINTS; HUMANS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, ERBB-2; S PHASE CELL CYCLE CHECKPOINTS; SIGNAL TRANSDUCTION;

EID: 84905113952     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2014.05.006     Document Type: Article

References (22)

1. Ferlay J., Shin H.R., Bray F., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 12:2893-2917.
2. Kaufman B., Mackey J.R., Clemens M.R., Bapsy P.P., Vaid A., Wardley Andrew, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 2009, 33:5529-5537.
3. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792.
4. Johansson M., Perssson J.L. Cancer therapy: targeting cell cycle regulators. Anti-Cancer Agents Med Chem 2008, 8:723-731.
5. Malumbres M., Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 2009, 9:153-166.
6. Satyanarayana A., Kaldis P. Mammalian cell-cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms. Oncogene 2009, 28:2925-2939.
7. Franke T.F. PI3K/Akt: getting it right matters. Oncogene 2008, 27:6473-6488.
8. Vivanco I., Sawyers C.L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002, 2:489-501.
9. Saxena N.K., Sharma D., Ding X.K., Lin S.B., Marra Fabioa, Merlin D., et al. Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Res 2007, 67:2497-2507.
10. Hennessy B.T., Smith D.L., Ram P.T., Lu Y., Mills G.B. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005, 4:988-1004.
11. Harper J.W., Adami G.R., Wei N., Keyomarsi K., Elledge S.J. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993, 4:805-816.
12. Sun L., Zhang S., Jiang Z., Huang X., Wang T., Huang X., et al. Triptolide inhibitsCOX-2 expression by regulating mRNA stability in TNF-alpha-treated A549cells. Biochem Biophys Res Commun 2011, 416:99-105.
13. Abbas T., Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 2009, 9:400-414.
14. Stewart A.Z., Westfall md, Pietenpol J.A. Cell-cycle dysregulation and anticancer therapy. Trends Pharmacol Sci 2003, 3:139-145.
15. Yong Z., Ransom J.F., Li A.K., Vedantham V., Drehle M., Muth A.N., et al. Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2. Cell 2007, 2:303-317.
16. Obaya A.J., Sedivy J.M. Regulation of cyclin-Cdk activity in mammalian cells. Cell Mol Life Sci 2002, 59:126-142.
17. Huynh N., Liu K.H., Baldwin G.S., He H. P21-activated kinase 1 stimulates colon cancer cell growth and migration/invasion via ERK- and AKT-dependent pathways. Biochim Biophys Acta 2010, 9:1106-1113.
18. Drobnjak M., Osman I., Scher H.I., Fazzari M., Cordon-Cardo C. Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone. Clin Cancer Res 2000, 6:1891-1895.
19. Fu M., Wang C., Li Z., Sakamaki T., Pestell R.G. Mini review. Cyclin D1: normal and abnormal functions. Endocrinology 2004, 145:5439-5447.
20. Junttila T.T., Akita R.W., Parsons K., Fields C., Lewis Phillips G.D., Friedman L.S., et al. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 2009, 15:429-440.
21. Staal S.P. Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America 1987, 84:5034-5037.
22. Wu R., Hu T.C., Rehemtulla A., Fearon E.R., Cho K.R. Preclinical testing of PI3K/AKT/mTOR signaling inhibitors in a mouse model of ovarian endometrioid adenocarcinoma. Clin Cancer Res 2011, 23:7359-7372.